Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Oy has extended its financial runway into Q3 2024 and reached an agreement with IPF for a waiver extension to continue funding the development of its leading drug candidate, bexmarilimab. The company has taken significant cash preservation measures and is actively working to secure longer-term financing for pivotal trials and commercial partnerships. Faron’s new CEO, Dr. Juho Jalkanen, expresses gratitude to all stakeholders for their support in this critical phase.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
